az

AstraZeneca vaccine suspended in 11 European countries

March 16, 2021
Manufacturing and Production AstraZeneca

Blood clot fears have caused 11 European countries to suspend the use of the Oxford-AstraZeneca vaccine. France, Germany, Italy, and …

gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

Perception and Otsuka enter collaboration and licensing deal for depression drug candidate

March 16, 2021
Manufacturing and Production CNS, Otsuka Pharmaceutical, Perception Neuroscience, depression

Perception Neuroscience and Otsuka Pharmaceutical have announced a collaboration and licensing agreement for the development and commercialisation of Perception’s lead …

A woman being given eye drops

Ocuphire’s pupil dilation treatment shows promising Phase III trial results

March 15, 2021
Sales and Marketing Ocuphire, eye treatment, nyxol

Ocuphire Pharma’s Nyxol treatment for pharmacologically-induced pupil dilation (mydriasis) has met its primary and secondary endpoints in its Phase III …

brain_scan_small

Newron and Zambon to collaborate on Parkinson’s dyskinesia drug trial

March 15, 2021
Sales and Marketing Newron Pharmaceuticals, Parkinson's, Zambon

Newron Pharmaceuticals and its partner Zambon have announced an agreement for a potentially pivotal study to evaluate the efficacy of …

Roche building

Roche acquire GenMark in $1.8 billion deal

March 15, 2021
Sales and Marketing Diagnostics, GenMark, Roche

Pharmaceutical giant Roche have bought GenMark Diagnostics in a deal worth $1.8 billion, expanding their infectious disease testing for illnesses …

astrazeneca_sign_sky

Netherlands suspends AstraZeneca vaccine despite safety assurances

March 15, 2021
Medical Communications, Sales and Marketing AstraZeneca, COVID-19, EMA, EU, WHO

The Netherlands has become the latest country to suspend the use of the Oxford-AstraZeneca vaccine amid concerns it may cause …

libtayo

Phase III trial of Libtayo stopped early after positive overall survival results

March 15, 2021
Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi

A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …

top 10 news roundup

Pharmafile.com’s top 10 news stories of the week

March 12, 2021
Medical Communications COVID-19, covid 19 news, covid-19 news, news, news roundup, pharma news

In the last week, a number of new treatment developments have made the news; for COVID-19, GSK and Vir’s monoclonal-antibody …

Kintor’s COVID-19 treatment reduces mortality by 92%

March 12, 2021
Medical Communications Brazil, Brazil variant, COVID-19, Kintor, covid-19 treatment

Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by 92%, in a clinical trial …

J&J’s one-shot COVID-19 vaccine approved by European Commission

March 12, 2021
Medical Communications COVID-19, EMA, Johnson & Johnson

The European Commission has granted Johnson and Johnson’s single-shot COVID-19 vaccine Conditional Marketing Authorisation (CMA), it was announced on Thursday. …

Novavax announces vaccine’s high efficacy against original and variant COVID-19 strains

March 12, 2021
Medical Communications COVID-19, Novavax, vaccines

Novavax has announced final efficacy of 96.4% against mild, moderate, and severe disease caused by the original COVID-19 strain in …

lonza

Altimmune expands COVID-19 vaccine manufacturing deal with Lonza

March 12, 2021
Medical Communications Altimmune, COVID-19, Lonza, vaccines

Altimmune has expanded its previously-announced AdCOVID vaccine manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated …

Eli Lilly building

Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial

March 11, 2021
COVID-19, Eli Lilly, covid-19 treatment

Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …

GSK building

GSK and Vir Biotechnology COVID-19 drug found to reduce deaths and hospitalisation by 85%

March 11, 2021
GSK, GlaxoSmithKline, Vir Biotechnology

Vir Biotechnology and GSK have announced that their monoclonal-antibody drug has been found to reduce hospitalisations or deaths from COVID-19 …

FDA building

FDA approves AVEO’s kidney cancer treatment

March 11, 2021
Aveo, FDA, Kidney cancer, fotivda, rcc

The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …

Complix and I-Mab sign deal to develop alphabody cancer therapies

March 11, 2021
Cancer, Complix, oncology

Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …

GSK to expand cell and gene therapy manufacturing capacity at CGT Catapult’s Stevenage site

March 11, 2021

GlaxoSmithKline (GSK) will expand its clinical trial manufacturing capacity for advanced therapy medicinal products (ATMP) at Cell and Gene Therapy …

coronavirus

Pharmafile.com’s weekly COVID-19 news round-up

March 10, 2021
Research and Development COVID, COVID Vaccine, COVID-19, coronavirus, covid round-up

The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with severe symptoms of the virus …

lilly_entrance_web

Lilly’s cancer drug Retsevmo gets UK approval for multiple indications

March 10, 2021
Research and Development Cancer, Eli Lilly, MHRA

The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.

The Gateway to Local Adoption Series

Latest content